Literature DB >> 24590059

Immunosurveillance by antiangiogenesis: tumor growth arrest by T cell-derived thrombospondin-1.

Keri L Schadler1, Erika J Crosby, Alice Yao Zhou, Dong Ha Bhang, Lior Braunstein, Kwan Hyuck Baek, Danielle Crawford, Alison Crawford, Jill Angelosanto, E John Wherry, Sandra Ryeom.   

Abstract

Recent advances in cancer immunotherapy suggest that manipulation of the immune system to enhance the antitumor response may be a highly effective treatment modality. One understudied aspect of immunosurveillance is antiangiogenic surveillance, the regulation of tumor angiogenesis by the immune system, independent of tumor cell lysis. CD4(+) T cells can negatively regulate angiogenesis by secreting antiangiogenic factors such as thrombospondin-1 (TSP-1). In tumor-bearing mice, we show that a Th1-directed viral infection that triggers upregulation of TSP-1 in CD4(+) and CD8(+) T cells can inhibit tumor angiogenesis and suppress tumor growth. Using bone marrow chimeras and adoptive T-cell transfers, we demonstrated that TSP-1 expression in the T-cell compartment was necessary and sufficient to inhibit tumor growth by suppressing tumor angiogenesis after the viral infection. Our results establish that tumorigenesis can be stanched by antiangiogenic surveillance triggered by an acute viral infection, suggesting novel immunologic approaches to achieve antiangiogenic therapy. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24590059      PMCID: PMC4061618          DOI: 10.1158/0008-5472.CAN-13-0094

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.

Authors:  Dhanalakshmi Chinnasamy; Zhiya Yu; Sid P Kerkar; Ling Zhang; Richard A Morgan; Nicholas P Restifo; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2012-01-30       Impact factor: 12.531

2.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

Authors:  Andrea Facciabene; Xiaohui Peng; Ian S Hagemann; Klara Balint; Andrea Barchetti; Li-Ping Wang; Phyllis A Gimotty; C Blake Gilks; Priti Lal; Lin Zhang; George Coukos
Journal:  Nature       Date:  2011-07-13       Impact factor: 49.962

3.  Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

Authors:  Dhanalakshmi Chinnasamy; Zhiya Yu; Marc R Theoret; Yangbing Zhao; Rajeev K Shrimali; Richard A Morgan; Steven A Feldman; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

4.  Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma.

Authors:  A I Sahora; A W Rusk; J Henkin; E M McKeegan; Y Shi; C Khanna
Journal:  J Vet Intern Med       Date:  2012-07-21       Impact factor: 3.333

5.  Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1.

Authors:  Sukhbir Kaur; Svetlana A Kuznetsova; Michael L Pendrak; John M Sipes; Martin J Romeo; Zhuqing Li; Lijuan Zhang; David D Roberts
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

Review 6.  Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth.

Authors:  Jack Lawler
Journal:  J Cell Mol Med       Date:  2002 Jan-Mar       Impact factor: 5.310

7.  IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen.

Authors:  G L Beatty; Y Paterson
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

8.  An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth.

Authors:  Erinn B Rankin; Duonan Yu; Jiu Jiang; Hao Shen; Edward J Pearce; Michael H Goldschmidt; David E Levy; Tatyana V Golovkina; Christopher A Hunter; Andrei Thomas-Tikhonenko
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

9.  DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth.

Authors:  Zhihua Ruan; Zhao Yang; Yiqin Wang; Huiming Wang; Yongwen Chen; Xiaoyun Shang; Chenying Yang; Sheng Guo; Junfeng Han; Houjie Liang; Yuzhang Wu
Journal:  J Immunother       Date:  2009-06       Impact factor: 4.456

10.  CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice.

Authors:  Vu Quang Van; Nobuyasu Baba; Manuel Rubio; Keiko Wakahara; Benoit Panzini; Carole Richard; Genevieve Soucy; Denis Franchimont; Genevieve Fortin; Ana Carolina Martinez Torres; Lauriane Cabon; Santos Susin; Marika Sarfati
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

View more
  9 in total

1.  Thrombospondin 1 and Its Diverse Roles as a Regulator of Extracellular Matrix in Fibrotic Disease.

Authors:  Joanne E Murphy-Ullrich
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

Review 2.  Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors.

Authors:  Kathrina L Marcelo-Lewis; Shhyam Moorthy; Ecaterina Ileana-Dumbrava
Journal:  J Immunother Precis Oncol       Date:  2020-08-05

Review 3.  The Genetic Basis of Dormancy and Awakening in Cutaneous Metastatic Melanoma.

Authors:  Agata Janowska; Michela Iannone; Cristian Fidanzi; Marco Romanelli; Luca Filippi; Marzia Del Re; Manuella Martins; Valentina Dini
Journal:  Cancers (Basel)       Date:  2022-04-23       Impact factor: 6.575

4.  Identification of plasma protein markers common to patients with malignant tumour and Abnormal Savda in Uighur medicine: a prospective clinical study.

Authors:  Halmurat Upur; Yin Chen; Mayila Kamilijiang; Wanli Deng; Xierzhatijiang Sulaiman; Renaguli Aizezi; Xiao Wu; Wuniqiemu Tulake; Abulizi Abudula
Journal:  BMC Complement Altern Med       Date:  2015-02-05       Impact factor: 3.659

5.  Mycobacterium bovis Bacillus Calmette-Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function.

Authors:  Ricardo D Lardone; Alfred A Chan; Agnes F Lee; Leland J Foshag; Mark B Faries; Peter A Sieling; Delphine J Lee
Journal:  Front Immunol       Date:  2017-08-11       Impact factor: 7.561

6.  Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy.

Authors:  Keri L Schadler; Nicholas J Thomas; Peter A Galie; Dong Ha Bhang; Kerry C Roby; Prince Addai; Jacob E Till; Kathleen Sturgeon; Alexander Zaslavsky; Christopher S Chen; Sandra Ryeom
Journal:  Oncotarget       Date:  2016-10-04

7.  Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression.

Authors:  Halime Kalkavan; Piyush Sharma; Stefan Kasper; Iris Helfrich; Aleksandra A Pandyra; Asmae Gassa; Isabel Virchow; Lukas Flatz; Tim Brandenburg; Sukumar Namineni; Mathias Heikenwalder; Bastian Höchst; Percy A Knolle; Guido Wollmann; Dorothee von Laer; Ingo Drexler; Jessica Rathbun; Paula M Cannon; Stefanie Scheu; Jens Bauer; Jagat Chauhan; Dieter Häussinger; Gerald Willimsky; Max Löhning; Dirk Schadendorf; Sven Brandau; Martin Schuler; Philipp A Lang; Karl S Lang
Journal:  Nat Commun       Date:  2017-03-01       Impact factor: 14.919

8.  Long non-coding RNA BZRAP1-AS1 silencing suppresses tumor angiogenesis in hepatocellular carcinoma by mediating THBS1 methylation.

Authors:  Weiwei Wang; Guoyong Chen; Bing Wang; Zhenhua Yuan; Guangbo Liu; Biao Niu; Yongfeng Chen; Shaotang Zhou; Junchuang He; Huanzhou Xue
Journal:  J Transl Med       Date:  2019-12-17       Impact factor: 5.531

Review 9.  Angiogenesis-related non-coding RNAs and gastrointestinal cancer.

Authors:  Zahra Sadat Razavi; Kasra Asgarpour; Maryam Mahjoubin-Tehran; Susan Rasouli; Haroon Khan; Mohammad Karim Shahrzad; Michael R Hamblin; Hamed Mirzaei
Journal:  Mol Ther Oncolytics       Date:  2021-05-15       Impact factor: 7.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.